- Joined
- 28 January 2008
- Posts
- 104
- Reactions
- 0
Fatmango, I think PRR still has a fair way to go until investors really start to get a hold of this one. There are still some hurdles to jump and if PRR can get over these, then we should see some interest at that stage.
US article published last week:
"'Plenty of investors, wary about the sharp market volatility in the U.S., continue to seek refuge on foreign shores for stocks that promise sizable growth potential without a stiff price. Australia's Prima BioMed could well be one of the names to consider."
Full article:
http://www.dailyfinance.com/story/i...-next-dendreo/19662217/?icid=sphere_copyright
Thanks for the link to the article RADV. Couldn't ask for a more heartening read on my little investment.
Out of blue PRR shot up by 33 %, massive volume , speeding ticket
I wonder if a newsletter becomes so effective for more than ten fold volume, 40% increase in one day intra day trading why does not it happen in all recommendations from the same newsletter.
I am cynical to say that there is more than just the newsletter here. Stinking like rotten fish.
Trailing one year: the value of $1,000 invested one year ago is $786 [vs $1,073 for the All Ordinaries index], for a capital loss of $214. The total return to shareholders for 1 year is -21.4%.
Trailing five years: the value of $1,000 invested five years ago is $1,141, for a capital gain of $141.
Out of blue PRR shot up by 33 %, massive volume , speeding ticket
I wonder if a newsletter becomes so effective for more than ten fold volume, 40% increase in one day intra day trading why does not it happen in all recommendations from the same newsletter.
I am cynical to say that there is more than just the newsletter here. Stinking like rotten fish.
With no news I don't see the rush to get into this stock, it will probably bleed back down to the 10 cent mark like it has before.
The more immediate potential is that PRR is aiming for listing on the NASDAQ. *IF* that happens then it's open to the US for trading on that arm and you have a gander at that exposure alone.
Sustained sp rises in boitech space feed off of both news and speculation of course. I would have said the recent rise would be short lived (in the abscene of trial news) but with the recent presentations in Boston and the JP Morgan one in advance of a NSADAQ listing I'm thinking now we may be looking at a 'new normal' in the sp. Where that is I don't know. If I had to guess I would say...
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?